Tubulis Receives FDA Fast Track Designation
Tubulis’ TUB-040, an ADC for platinum-resistant ovarian cancer, receives FDA Fast Track, expediting its development in Phase I/IIa trials to address urgent cancer treatment needs.
OCCIDENT
We invest in deep tech start-ups with a focus on spin-offs originating from
scientific research. What motivates us is having a real impact and enabling
concrete solutions for different challenges facing society today.
scientific research. What motivates us is having a real impact and enabling
concrete solutions for different challenges facing society today.
As a venture capital investor, we support start-ups from the seed stage onwards and enable founding teams to achieve outstanding results. With a strong entrepreneurial mindset, we invest our own money and make decisions based on sustainable potential for success.
Portfolio
Co-operation with the founding teams of our portfolio companies motivates and inspires us every day. We are energized by their passion and drive, and the often very intense exchange spurs us on to tackle challenges together.
Want to learn more about OCCIDENT?
OCCIDENT in numbers
Portfolio News
Tubulis Doses First Patient in Phase I/IIa Trial for TUB-040
UB-040 targets an overexpressed antigen in ovarian and lung adenocarcinoma. The trial will enroll up to 140 patients across the US, UK, and Europe.
Avelo collaborates with global health leaders in project “BreathForDiagnosis”
The €3 million research project is funded by the European Commission under “Horizon Europe”, and co-funded by the Swiss State Secretariat for Education, Research and Innovation (SERI).
The Science Investor.
The OCCIDENT Team
Curious, perceptive, grounded and courageous, yet also humorous and team-oriented – that is the OCCIDENT team. As experts in our field, we know exactly what we are doing.
